Novartis Vymada Patent Revoked, Entresto patent cancelled India,

India Cancels Novartis Vymada Patent, Opens Market to Generics

A major update has been released by the Indian Patent Office (IPO) that could significantly reshape the Indian pharmaceutical market. Novartis Vymada Patent Revoked in India. The IPO has revoked/canceled the patent held by Novartis, the Swiss multinational pharmaceutical giant based in Basel, Switzerland, on its blockbuster cardiac drug Vymada (also known globally as Entresto). […]

how to tackle patent eligibilitu issues across multiple jurisdictions

Patent Eligibility Across Jurisdictions: What You Need to Know

Patenting is very complex and involves multiple stages, and the complexity increases when we try to file a patent in multiple regions or countries. In 2024–25, India granted around 26,000 patents out of 78,000 applications, meaning nearly 67% were rejected or not granted, mainly due to non-eligibility, lack of novelty, or poor documentation. To deal […]